
Altimmune, Inc.
100
Recent developments include the release of third quarter 2026 financial results, loan agreement tranche drawdown, board appointments, and updates on clinical development progress for pemvidutide.
- Altimmune reported third quarter 2026 financial results, highlighting $480 million in cash and investments as of September 30, 2026, with a net loss of $31.6 million and EPS of -$0.15 [N1].
- The company held a Q3 2026 earnings call discussing clinical progress and financial position [N2].
- Altimmune drew $10.0 million tranche three under its loan agreement with Hercules Capital in October 2026 [N3].
- Peter Greenleaf and Alex Howarth were appointed to the Board of Directors in October 2026 [N4].
- The company detailed pemvidutide’s development path toward a liver-disease franchise, emphasizing ongoing clinical trials [N5].
- Altimmune's stock price increased by 14.2% since the last earnings report, reflecting market interest [N6].
- Discussions highlighted rising cash balances alongside execution risks related to clinical development and commercialization [N7].
- Industry context includes competitor pipeline developments impacting market dynamics [N8].
Altimmune, Inc. operates as a clinical-stage biopharmaceutical company developing novel vaccines and therapeutics, with a focus on metabolic and liver diseases. Its lead product candidate, pemvidutide, is in Phase 3 clinical trials targeting MASH, with additional trials for alcohol use disorder and alcohol-associated liver disease. The company has not yet generated revenue from product sales and relies on government grants, equity financing, and debt to fund operations. Research and development expenses constitute the majority of operating costs, reflecting ongoing clinical trial activities and manufacturing of clinical materials. General and administrative expenses have increased due to expanded headcount and public company compliance. Altimmune maintains a strong liquidity position with substantial cash, cash equivalents, and short-term investments as of September 30, 2026. The company has a term loan facility with Hercules Capital and has raised capital through registered direct offerings and at-the-market programs. Recent corporate developments include new board member appointments and relocation of headquarters to New Jersey.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics primarily for metabolic and liver diseases, with a lead candidate pemvidutide undergoing Phase 3 trials for MASH. The company has not generated product revenue and incurs significant R&D and operating expenses. As of September 30, 2026, Altimmune held approximately $28.9 million in cash and cash equivalents and $236.2 million in short-term investments, with a strong liquidity position reflected in a current ratio of 23.93. The company finances operations through equity offerings and a structured term loan facility. Recent developments include FDA Breakthrough Therapy designation for pemvidutide, new board appointments, and ongoing clinical trial progress.
Altimmune's lead candidate, pemvidutide, has advanced to Phase 3 clinical trials for MASH and received FDA Breakthrough Therapy designation, indicating regulatory recognition of its potential. The company has demonstrated the ability to raise capital through equity offerings and structured debt, supporting ongoing clinical development. Its strong liquidity position provides operational runway. The addition of experienced board members and relocation to New Jersey may support strategic growth and operational efficiency. Continued clinical progress and regulatory milestones could enhance the company's development pipeline and value proposition.
Altimmune has not generated product revenue and continues to incur significant net losses and negative cash flows from operations, reflecting the high costs and risks inherent in clinical-stage biopharmaceutical development. Clinical trial outcomes remain uncertain, and regulatory approvals are not guaranteed. The company depends on external financing, including equity offerings and debt facilities, which may dilute shareholders or increase financial obligations. Execution risks include potential delays or failures in clinical trials, regulatory hurdles, and operational challenges associated with scaling and commercialization. Market competition and changing regulatory environments also pose risks.
Altimmune's moat is primarily based on its proprietary clinical-stage drug candidates, particularly pemvidutide, which has received FDA Breakthrough Therapy designation for MASH. The company's specialized focus on metabolic and liver diseases and ongoing clinical development programs provide potential differentiation. However, as a clinical-stage biopharmaceutical company without approved products or revenues, its competitive position depends heavily on successful clinical trial outcomes and regulatory approvals. The company's ability to secure financing and manage development risks also influences its competitive moat.
• Clinical Development Risk: The success of Altimmune's product candidates, including pemvidutide, depends on the outcomes of ongoing and future clinical trials, which are inherently uncertain and may require additional time and resources.
• Regulatory Risk: Obtaining regulatory approvals involves complex processes and changing requirements; failure to secure approvals would impede commercialization efforts.
• Financial Risk: The company has incurred significant losses and negative cash flows, relying on external financing which may not be available on favorable terms, potentially impacting operations and shareholder value.
• Execution Risk: Operational challenges such as manufacturing, clinical trial enrollment, and scaling commercial operations may affect the company's ability to advance its pipeline and prepare for market launch.
• Market and Competitive Risk: Competition from other biopharmaceutical companies and evolving market dynamics may affect the commercial potential of Altimmune's product candidates.
Business trends: Continued clinical development of pemvidutide and other candidates with regulatory designations and capital raises supporting operations.
Execution milestones: Progression through Phase 3 trials, loan tranche drawdowns, and board strengthening.
Key risks: Clinical trial uncertainties, regulatory approval challenges, financial reliance on external funding, and operational execution risks.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing novel vaccines and therapeutics, with a significant focus on the development of pemvidutide, a drug candidate targeting metabolic and liver diseases including MASH (metabolic dysfunction-associated steatohepatitis).
- The company has not generated revenue from product sales to date; prior revenues were primarily from government and foundation grants supporting research projects.
- Research and development expenses are the primary operating expenses, including costs for clinical trials, employee-related expenses, manufacturing clinical trial materials, and regulatory operations.
- Altimmune conducts Phase 3 clinical trials for pemvidutide in MASH and clinical trials for AUD (alcohol use disorder) and ALD (alcohol-associated liver disease).
- General and administrative expenses include salaries, stock-based compensation, professional fees, insurance, and facility costs, and have increased due to higher headcount and public company compliance costs.
- The company has incurred significant losses since inception and has an accumulated deficit of $649.5 million as of December 31, 2025.
- Altimmune's liquidity as of September 30, 2026 includes $28.9 million in cash and cash equivalents, $236.2 million in short-term investments, and total current assets of $275.8 million against current liabilities of $11.5 million, resulting in a current ratio of 23.93 and a cash ratio of 23.
- The company has a term loan facility with Hercules Capital, structured in four tranches totaling up to $125 million, with $10 million drawn in the third tranche as of October 29, 2026.
- Altimmune completed a registered direct offering in early 2026 raising approximately $70.4 million in net proceeds, with additional at-the-market offerings raising over $140 million since 2025.
- The company relocated its headquarters to New Jersey as of mid-2026.
- Pemvidutide received FDA Breakthrough Therapy designation for MASH in early 2026.
- Recent financial results for Q3 2026 show net loss of $31.6 million and EPS of -$0.15, with cash and investments totaling approximately $480 million.
- The company appointed new board members Peter Greenleaf and Alex Howarth in October 2026.
- Altimmune's research and development expenses decreased by 19% in 2025 compared to 2024, primarily due to completion of certain clinical trials and winding down of some activities, partially offset by new trials for AUD and ALD.
- The company continues to invest in clinical trial materials manufacturing and discovery projects.
- Altimmune's operating expenses and net losses reflect ongoing investment in clinical development and preparation for potential commercialization.
- The company has not generated positive cash flows from operations and relies on equity and debt financing to fund operations.
Generated 2026-11-13
- N2
- S1 | 2026-03-06 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-13 | www.nasdaq.com | Altimmune, Inc. Reports Third Quarter 2026 Financial Results and $480 million in Cash and Investments | https://www.nasdaq.com/articles/altimmune-inc-reports-third-quarter-2026-financial-results-and-480-million-cash-and
- N2 | 2026-11-12 | www.nasdaq.com | Altimmune (ALT) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/altimmune-alt-q3-2026-earnings-call-transcript
- N3 | 2026-10-29 | www.nasdaq.com | Altimmune, Inc. Draws $10.0 million Tranche Three Under Loan Agreement | https://www.nasdaq.com/articles/altimmune-inc-draws-100-million-tranche-three-under-loan-agreement
- N4 | 2026-10-27 | www.nasdaq.com | Altimmune, Inc. Appoints Peter Greenleaf and Alex Howarth to Board of Directors | https://www.nasdaq.com/articles/altimmune-inc-appoints-peter-greenleaf-and-alex-howarth-board-directors
- N5 | 2026-10-01 | www.nasdaq.com | Altimmune Details Pemvidutide’s Path Toward a Liver-Disease Franchise | https://www.nasdaq.com/articles/altimmune-details-pemvidutides-path-toward-liver-disease-franchise
- N6 | 2026-09-11 | www.nasdaq.com | Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report? | https://www.nasdaq.com/articles/why-altimmune-alt-142-last-earnings-report
- N7 | 2026-08-19 | www.nasdaq.com | Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger? | https://www.nasdaq.com/articles/altimmune-worth-buying-cash-rises-execution-risks-linger
- N8 | 2026-08-14 | www.nasdaq.com | Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus | https://www.nasdaq.com/articles/kodiaks-q2-loss-wider-expected-pipeline-development-focus
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


